The Duke-Margolis Institute for Health Policy, under a cooperative agreement with the U.S. Food and Drug Administration, is convening a one-day hybrid public meeting on September 17, 2025 focused on novel efficacy endpoints used in interventional clinical trials for drugs and biologics intended for patients with severe vision loss.